Expansion Opportunities SCIEX is actively expanding its ZenoTOF accurate mass platform and forming strategic partnerships (e.g., Ion Opticks) to broaden access to advanced LC solutions in proteomics. This signals potential sales opportunities for enhanced mass spectrometry systems, LC columns, and related software or services.

ASMS Presence Frequent participation and platform-wide announcements at major conferences like ASMS 2026 indicate SCIEX targets high-visibility product launches and demonstrations. This presents timely touchpoints for upsell of instrumentation, software, service contracts, and automation solutions aligned with new releases.

Integrated Solutions Recent product updates include native fluorescence detection on BioPhase 8800 and OS software version 4.0 enhancing automation. This highlights cross-sell opportunities for customers needing integrated hardware, detection modalities, and software-driven workflow optimization.

Strategic Acquisitions Past asset divestiture and CRO collaborations (e.g., Veloxity Labs acquisition of ZenoTOF 8600 components) point to a market shift toward flexible, rapid analytics solutions. Opportunities exist to position SCIEX instruments and service ecosystems to CROs and contract research buyers seeking scalable, fast-turnaround capabilities.

Proteomics Focus Partnerships expanding access to advanced LC solutions for proteomics (Aurora XS columns) indicate strong demand in this segment. Targeted sales efforts could focus on proteomics labs, method development, and column consumables to drive instrument utilization and long-term service revenue.